- Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1)
- Interventions
- Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Macon, Georgia • Austin, Texas • Bellaire, Texas + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 36
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV
- Interventions
- Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), Feasibility of Intervention Measure (FIM), HIV Stigma Scale Questionnaire, HIV Treatment Satisfaction Questionnaire status version (HIVTSQs12), HIV Treatment Satisfaction Questionnaire change version (HIVTSQc12), Needs and Barriers Assessment, Pre-visit Outreach, Qualitative interview - patient participants, Staff education, Staff Month 7 and 15 Survey - Staff Burden and Engagement, Qualitative interview - staff
- Behavioral
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 4
- States / cities
- Harlan, Iowa • Shenandoah, Iowa • Grand Island, Nebraska + 1 more
- Conditions
- HIV Infections
- Interventions
- DTG/3TC, Cabotegravir (CAB) LA, Rilpivirine (RPV) LA
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Bakersfield, California • Fort Lauderdale, Florida + 12 more
- Conditions
- HIV
- Interventions
- rilpivirine/cabotegravir
- Drug
- Lead sponsor
- Whitman-Walker Institute
- Government
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia
- Conditions
- HIV-1-infection
- Interventions
- Once daily CAB tablet + RPV tablet, Long acting CAB injectable + long acting RPV injectable
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Memphis, Tennessee
- Conditions
- Hiv
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Auburn, Alabama • San Francisco, California • Fort Lauderdale, Florida + 1 more
- Conditions
- Healthy
- Interventions
- RPV LA, CAB LA
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Salt Lake City, Utah
- Conditions
- HIV Infections
- Interventions
- Standard of Care (SOC) Oral ART, Oral RPV, Oral CAB, RPV-LA Loading Dose, CAB-LA Loading Dose, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more
- Conditions
- HIV Infections
- Interventions
- CAB LA+RPV LA
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 9
- States / cities
- Sacramento, California • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more
- Conditions
- HIV Infections
- Interventions
- Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 631 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more
- Conditions
- HIV Infections
- Interventions
- Cabotegravir Tablets, Rilpivirine Tablets, Cabotegravir extended release suspension for injection (long-acting), Rilpivirine extended release suspension for injection (long-acting)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- HIV Infections
- Interventions
- Lenacapavir, Lenacapavir Tablet, Teropavimab, Zinlirvimab, Cabotegravir, Rilpivirine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 16
- States / cities
- San Francisco, California • DeLand, Florida • Fort Lauderdale, Florida + 12 more
- Conditions
- HIV Infections
- Interventions
- Cabotegravir Tablets, Rilpivirine Tablets, Cabotegravir Injectable Suspension, Rilpivirine Injectable Suspension
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,049 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 33 more
- Conditions
- HIV-1-infection
- Interventions
- Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 689 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 40
- States / cities
- Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more
- Conditions
- HIV Treatment, HIV Prevention
- Interventions
- At Home Self-Collections
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- HIV Infections
- Interventions
- Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets, Rilpivirine Injectable Suspension (RPV LA), BIKTARVY Tablets (BIK)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 687 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 41
- States / cities
- Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more
- Conditions
- Hiv
- Interventions
- Collaborative drug therapy management model, Cabotegravir/Rilpivirine
- Behavioral · Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Infections, Human Immunodeficiency Virus and Hepatitis
- Interventions
- Dolutegravir, Rlipivirine, GSK1265744
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- HIV Infections
- Interventions
- CAB LA + RPV LA, Oral ART
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more
- Conditions
- HIV-1-infection, Medication Adherence, Satisfaction, Patient
- Interventions
- Home visit delivery strategy
- Other
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- HIV -1 Infection
- Interventions
- Every 4-week long-acting injectable cabotegravir and rilpivirine
- Drug
- Lead sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 10
- States / cities
- La Jolla, California • Los Angeles, California • Aurora, Colorado + 7 more
- Conditions
- HIV Infections
- Interventions
- CABENUVA
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 15
- States / cities
- Evans, Georgia • East Lansing, Michigan • Novi, Michigan + 12 more
- Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1)
- Interventions
- Cabotegravir Injectable Suspension, Rilpivirine Injectable Suspension
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 10
- States / cities
- Bakersfield, California • Fort Lauderdale, Florida • Ft. Pierce, Florida + 7 more
- Conditions
- HIV Infections
- Interventions
- CAB-RPV LA, Standard treatment within an HIV clinic
- Other
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts